-
EP3782617
European procedure
Extract from the Register of European Patents
EP About this file: EP3782617
| EP3782617 - PHARMACEUTICAL GEL COMPOSITIONS COMPRISING LEVODOPA, CARBIDOPA AND ENTACAPONE [Right-click to bookmark this link] | |||
| Former [2021/08] | PHARMACEUTICAL GEL COMPOSITIONS COMPRISING LEVODOPA, CARBIDOPA AND ENTACAPON | ||
| [2023/11] | Status | No opposition filed within time limit Status updated on 08.11.2024 Database last updated on 31.03.2026 | |
| Former | The patent has been granted Status updated on 01.12.2023 | ||
| Former | Grant of patent is intended Status updated on 25.07.2023 | ||
| Former | Examination is in progress Status updated on 30.06.2023 | ||
| Former | Grant of patent is intended Status updated on 16.03.2023 | ||
| Former | Examination is in progress Status updated on 17.12.2021 | ||
| Former | Request for examination was made Status updated on 27.08.2021 | ||
| Former | The application has been published Status updated on 22.01.2021 | Most recent event Tooltip | 30.01.2026 | Lapse of the patent in a contracting state New state(s): CY | published on 04.03.2026 [2026/10] | Applicant(s) | For all designated states LobSor Pharmaceuticals Aktiebolag Kålsängsgränd 10 D 753 19 Uppsala / SE | [2021/08] | Inventor(s) | 01 /
Bolsöy, Roger Kolonivägen 16 741 44 KNIVSTA / SE | [2021/08] | Representative(s) | Brann AB P.O. Box 3690 Sveavägen 63 103 59 Stockholm / SE | [2024/01] |
| Former [2021/08] | Brann AB P.O. Box 3690 Drottninggatan 27 103 59 Stockholm / SE | Application number, filing date | 20200070.9 | 04.09.2015 | [2021/08] | Priority number, date | SE20140051034 | 04.09.2014 Original published format: SE 1451034 | SE20150050344 | 24.03.2015 Original published format: SE 1550344 | [2021/08] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3782617 | Date: | 24.02.2021 | Language: | EN | [2021/08] | Type: | B1 Patent specification | No.: | EP3782617 | Date: | 03.01.2024 | Language: | EN | [2024/01] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 18.01.2021 | Classification | IPC: | A61K31/198, A61K31/277, A61K9/06, A61K47/38, A61P25/16, A61P25/28 | [2021/08] | CPC: |
A61K31/198 (EP,US);
A61K31/165 (EP,US);
A61K31/277 (EP,US);
A61K45/06 (EP,US);
A61K47/38 (EP,US);
A61K9/0019 (EP,US);
A61K9/0024 (EP,US);
A61K9/06 (EP,US);
A61K9/1652 (US);
| C-Set: |
A61K31/165, A61K2300/00 (US,EP);
A61K31/198, A61K2300/00 (US,EP);
A61K31/277, A61K2300/00 (US,EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/39] |
| Former [2021/08] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | PHARMAZEUTISCHE GELZUSAMMENSETZUNGEN MIT LEVODOPA, CARBIDOPA UND ENTACAPON | [2023/11] | English: | PHARMACEUTICAL GEL COMPOSITIONS COMPRISING LEVODOPA, CARBIDOPA AND ENTACAPONE | [2023/11] | French: | COMPOSITIONS PHARMACEUTIQUES SOUS FORME DE GEL COMPRENANT DE LA LÉVODOPA, CARBIDOPA ET ENTACAPONE | [2021/08] |
| Former [2021/08] | PHARMAZEUTISCHE ZUSAMMENSETZUNGEN IN FORM EINES GELS MIT LEVODOPA, CARBIDOPA UND ENTACAPON | ||
| Former [2021/08] | PHARMACEUTICAL GEL COMPOSITIONS COMPRISING LEVODOPA, CARBIDOPA AND ENTACAPON | Examination procedure | 24.08.2021 | Examination requested [2021/39] | 24.08.2021 | Date on which the examining division has become responsible | 17.12.2021 | Despatch of a communication from the examining division (Time limit: M04) | 21.03.2022 | Reply to a communication from the examining division | 17.03.2023 | Communication of intention to grant the patent | 27.06.2023 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 26.07.2023 | Communication of intention to grant the patent | 24.11.2023 | Fee for grant paid | 24.11.2023 | Fee for publishing/printing paid | 24.11.2023 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP15838800.9 / EP3188725 | Divisional application(s) | EP23219005.8 / EP4356907 | Opposition(s) | 07.10.2024 | No opposition filed within time limit [2024/50] | Fees paid | Renewal fee | 05.10.2020 | Renewal fee patent year 03 | 05.10.2020 | Renewal fee patent year 04 | 05.10.2020 | Renewal fee patent year 05 | 05.10.2020 | Renewal fee patent year 06 | 17.09.2021 | Renewal fee patent year 07 | 15.09.2022 | Renewal fee patent year 08 | 15.09.2023 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | CY | 04.09.2015 | EE | 03.01.2024 | LT | 03.01.2024 | LV | 03.01.2024 | MC | 03.01.2024 | SM | 03.01.2024 | GR | 04.04.2024 | IS | 03.05.2024 | LU | 04.09.2024 | [2026/10] |
| Former [2025/26] | EE | 03.01.2024 | |
| LT | 03.01.2024 | ||
| LV | 03.01.2024 | ||
| MC | 03.01.2024 | ||
| SM | 03.01.2024 | ||
| GR | 04.04.2024 | ||
| IS | 03.05.2024 | ||
| LU | 04.09.2024 | ||
| Former [2025/22] | EE | 03.01.2024 | |
| LT | 03.01.2024 | ||
| LV | 03.01.2024 | ||
| MC | 03.01.2024 | ||
| SM | 03.01.2024 | ||
| GR | 04.04.2024 | ||
| IS | 03.05.2024 | ||
| Former [2024/48] | EE | 03.01.2024 | |
| LT | 03.01.2024 | ||
| LV | 03.01.2024 | ||
| SM | 03.01.2024 | ||
| GR | 04.04.2024 | ||
| IS | 03.05.2024 | ||
| Former [2024/47] | LT | 03.01.2024 | |
| LV | 03.01.2024 | ||
| SM | 03.01.2024 | ||
| GR | 04.04.2024 | ||
| IS | 03.05.2024 | ||
| Former [2024/36] | LT | 03.01.2024 | |
| LV | 03.01.2024 | ||
| GR | 04.04.2024 | ||
| IS | 03.05.2024 | ||
| Former [2024/34] | LT | 03.01.2024 | |
| GR | 04.04.2024 | ||
| IS | 03.05.2024 | ||
| Former [2024/33] | LT | 03.01.2024 | |
| IS | 03.05.2024 | ||
| Former [2024/32] | IS | 03.05.2024 | Documents cited: | Search | [A] US2013253056 (NEMAS MARA et al.) | [AD] WO2009098661 (WOCKHARDT RESEARCH CENTER et al.) | [A] WO2010134074 (NEURODERM LTD et al.) | [A] PAOLO SOLLA ET AL: "Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo?)", NEUROPSYCHIATRIC DISEASE AND TREATMENT, vol. 6, 1 January 2010 (2010-01-01), pages 483 - 490, XP055416631, DOI: 10.2147/NDT.S5190 DOI: http://dx.doi.org/10.2147/NDT.S5190 | [A] C WARREN OLANOW ET AL: "Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study", LANCET NEUROLOGY, vol. 13, no. 2, 1 February 2014 (2014-02-01), GB, pages 141 - 149, XP055416633, ISSN: 1474-4422, DOI: 10.1016/S1474-4422(13)70293-X DOI: http://dx.doi.org/10.1016/S1474-4422(13)70293-X | [A] NYHOLM D ET AL: "Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial", EUROPEAN JOURNAL OF NEUROLOGY, RAPID SCIENCE PUBLISHERS, GB, vol. 19, no. 6, 1 June 2012 (2012-06-01), pages 820 - 826, XP002724127, ISSN: 1351-5101, [retrieved on 20111205], DOI: 10.1111/J.1468-1331.2011.03614.X DOI: http://dx.doi.org/10.1111/j.1468-1331.2011.03614.x | by applicant | US6500867 | US6797732 | WO2008053297 | WO2012147099 | US2006222703 | WO2009098661 | US5635213 | EP0670713 | EP0444899 | EP1670450 | WO2007138086 | WO2012066538 | FORSBERG ET AL., JPET, vol. 304, 1 February 2003 (2003-02-01), pages 498 | STALEVO, SUMMARY OF PRODUCT CHARACTERISTICS, 3 September 2015 (2015-09-03), Retrieved from the Internet |